Evercore analysts highlighted the company’s innovation in developing a novel oral formulation of LSD, with its lead asset ... added the stock in December, which analysts noted could bolster ...

MindBio is a psychedelic biopharmaceutical stock creating treatments for mental health conditions. Its lead drug candidate, MB22001, is a proprietary form of LSD designed for take-home microdosing.